By Regulatory Approvals — FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata PR Newswire
Read the original at Regulatory Approvals ↗
Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 25, 2026.